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Abstract
Type 2 diabetes is a leading cause of morbidity and mortality. While genetic variants have been found to influence the risk
of type 2 diabetes mellitus, relatively few studies have focused on genes associated with glycated hemoglobin, an index of
the mean blood glucose concentration of the preceding 8–12 weeks. Epidemiologic studies and randomized clinical trials
have documented the relationship between glycated hemoglobin levels and the development of long-term complications
in diabetes; moreover, higher glycated hemoglobin levels in the subdiabetic range have been shown to predict type 2
diabetes risk and cardiovascular disease. To examine the common genetic determinants of glycated hemoglobin levels, we
performed a genome-wide association study that evaluated 337,343 SNPs in 14,618 apparently healthy Caucasian women.
The results show that glycated hemoglobin levels are associated with genetic variation at the GCK (rs730497;
P=2.8 610
212), SLC30A8 (rs13266634; P=9.8610
28), G6PC2 (rs1402837; P=6.8610
210), and HK1 (rs7072268;
P=6.4610
29) loci. While associations at the GCK, SLC30A8, and G6PC2 loci are confirmatory, the findings at HK1 are
novel. We were able to replicate this novel association in an independent validation sample of 455 additional non-diabetic
men and women. HK1 encodes the enzyme hexokinase, the first step in glycolysis and a likely candidate for the control of
glucose metabolism. This observed genetic association between glycated hemoglobin levels and HK1 polymorphisms paves
the way for further studies of the role of HK1 in hemoglobin glycation, glucose metabolism, and diabetes.
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Introduction
Type 2 diabetes is a leading cause of morbidity and mortality.
While genetic variants influence the risk of type 2 diabetes mellitus
[1], relatively little is known about the role of genetic variations in
the regulation of glucose concentration in healthy individuals.
Indeed,only two genes,glucokinase (GCK) [2–4] and G6PC2 [5,6],
have been unequivocally associated with fasting blood glucose
concentration in healthy subjects. Other genes, such as SLC30A8,
have been linked to glucose metabolism without ever having been
associated with blood glucose concentration per se [7].
Glycated proteins are formed post-translationally from the slow,
non-enzymatic attachment of glucose to N-terminal valine and
internal lysine amino groups [8]. The concentration of glycated
hemoglobin is a function of the concentration of glucose to which
the erythrocytes are exposed over their lifespan (120 days on
average). The glycated hemoglobin assay reflects the integrated
blood glucose concentration of the preceding 8–12 weeks [9],
provides a better estimate of mean glycemia than routine
determinations of blood glucose concentration, and is the most
widely used index of chronic glycemia [10,11]. Clinical trials have
documented the relationship between glycated hemoglobin levels
and the development of long-term complications in type 1 and
type 2 diabetes [12,13], and higher glycated hemoglobin levels in
the subdiabetic range have been shown to predict type 2 diabetes
risk [14] and cardiovascular disease [14–17].
Despite considerable effort to decipher the genetic basis of type
2 diabetes, relatively few studies have focused on the genetic basis
of glycated hemoglobin levels. To examine the common genetic
determinants of glycated hemoglobin levels, we performed a
genome-wide association study evaluating 337,343 SNPs in 14,618
apparently healthy non-diabetic women of Caucasian ancestry.
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WGHS Study Participants
The study population derived from the Women’s Genome
Health Study (WGHS) [18]. Briefly, participants in the WGHS
include women from the United States Women’s Health Study
(WHS) with no prior history of cardiovascular disease, cancer, or
other major chronic illness [19]. All participants provided a blood
sample at the time of study enrollment from which genomic DNA
was extracted.
For all WGHS participants, baseline glycated hemoglobin
(HbA1c) was measured using the Tina-Quant turbidimetric
inhibition immunoassay (Roche Diagnostics, Indianapolis, Ind)
on a Hitachi 911 autoanalyzer using packed red blood cells. This
assay is standardized against the approved International Federa-
tion of Clinical Chemists reference method and has a coefficient of
variation of 7.2%. In addition to excluding women with self-
reported diabetes at baseline, individuals with glycated hemoglo-
bin of 7.0% or more were removed from analysis as this level has
been proposed as diagnostic of drug-requiring diabetes [20]. The
study was approved by the institutional review board of the
Brigham and Women’s Hospital.
Genotyping
DNA samples were genotyped with the Infinium II technology
from Illumina. Either the HumanHap300 Duo-Plus chip or the
combination of the HumanHap300 Duo and I-Select chips was
used. In either case, the custom content was identical and
consisted of candidate SNPs chosen without regard to allele
frequency to increase coverage of genetic variation with impact on
biological function including metabolism, inflammation or cardio-
vascular diseases. Genotyping at 318,237 HumanHap300 Duo
SNPs and 45,571 custom content SNPs was attempted, for a total
of 363,808 SNPs. Genetic context for all annotations are derived
from human genome build 36.1 and dbSNP build 126.
SNPs with call rates ,90% were excluded from further analysis.
Likewise, all samples with percentage of missing genotypes higher
than 2% were removed (N=1426). No obvious bias distinguished
failed from successful samples and failures are therefore assumed
to be the result of random technical artifacts. Among retained
samples, SNPs were evaluated for deviation from Hardy-Weinberg
equilibrium using an exact method [21] and were excluded when
the P-value was lower than 10
26. Samples were further validated
by comparison of genotypes at 44 SNPs that had been previously
ascertained using alternative technologies. SNPs with minor allele
frequency .1% in Caucasians were used for analysis. After quality
control, 308,625 HumanHap300 Duo SNPs and 28,718 custom
content SNPs were left, for a total of 337,343 SNPs.
Population Stratification
Because population stratification can result in inflated type I
error in genome-wide association analysis, a principal component
analysis using 1443 ancestry informative SNPs was performed
using PLINK [22] in order to confirm self-reported ancestry.
Briefly, these SNPs were chosen based on Fst.0.4 in HapMap
populations (YRB, CEU, CHB+JPT) and inter-SNP distance at
least 500 kb in order to minimize linkage disequilibrium. Different
ethnic groups were clearly distinguished with the two first
components. Based on this analysis, 58 individuals were excluded
from further evaluation as they did not cluster with other
Caucasians, leaving 14,618 participants for the current study
population. Two additional steps were taken to rule out the
possibility that residual stratification within Caucasians was
responsible for the associations observed. First, association analysis
was done with correction by genomic control. Second, a principal
component analysis [23] was performed in previously identified
Caucasians (only) using 124,931 SNPs chosen to have pair-wise
linkage disequilibrium lower than r
2=0.4. The first ten compo-
nents were then used as covariates in the association analysis. As
adjustment by these covariates did not change the conclusions, we
present analysis among Caucasian participants without further
correction for sub-Caucasian ancestry. The value of the genomic
control was 1.03916 before adjustment for the first ten
components and 1.03328 after adjustment.
Association Analysis
To identify common genetic variants influencing glycated
hemoglobin levels, we first attempted to discover which loci
significantly contributed to glycated hemoglobin concentration.
Glycated hemoglobin concentrations were adjusted for age,
menopause and body mass index using a linear regression model
in R to reduce the impact of clinical covariates on glycated
hemoglobin variance. The normal distribution of adjusted
glycated hemoglobin values was checked by visual inspection of
the normal Quantile-Quantile plot. Adjusted glycated hemoglobin
values were then tested for association with SNP genotypes by
linear regression in PLINK [22], assuming an additive contribu-
tion of each minor allele [24]. Beta coefficients are given using the
major allele as the reference allele (major and minor alleles are
presented in Supplementary Table S2). We also tested for
association using genotypic, recessive and dominant genetic
models. Since no additional locus was identified using these
models we only present the results of the additive genetic model. A
conservative P-value cut-off of 5610
28 was used to correct for the
maximum of 1,000,000 independent statistical tests thought to
correspond to all the common genetic variation of the human
genome [25]. The false discovery rate was also calculated as
described by Benjamini and Hochberg [26].
Once any locus with genome-wide significance was identified, a
forward selection linear multiple regression model was used to
further define the extent of the genetic association. Briefly, all
genotyped SNPs within 100 kb of the most significantly associated
SNP at each locus and passing quality control requirements were
tested for possible incorporation into a multiple regression model.
Author Summary
Type 2 diabetes is a leading cause of morbidity and
mortality in both the developed and developing world.
Because the main metabolic characteristic of diabetes is
increased blood glucose concentration, we sought to
uncover the genetic determinants of glycated hemoglo-
bin, an index of the mean blood glucose concentration of
the preceding 8–12 weeks. Taking advantage of new
technologies allowing us to interrogate genetic variation
on a whole-genome basis, we found that variations in the
GCK, SLC30A8, G6PC2, and HK1 genes are important
determinants of glycated hemoglobin concentrations.
While associations with the GCK, SLC30A8, and G6PC2
genes have previously been identified in genetic studies of
diabetes and blood glucose concentration, the findings at
HK1 are novel. HK1 encodes the enzyme hexokinase,
responsible for the first step in glucose utilization and a
likely candidate for the control of glucose metabolism. This
observed genetic association between glycated hemoglo-
bin levels and HK1 genetic variants paves the way for
further studies of the role of HK1 in glucose metabolism
and diabetes.
Association of HK1 with Glycated Hemoglobin
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smallest P-value among all the SNPs not yet included in the model
and if it was statistically significant after adjusting for multiple
comparisons. SNPs selected by this algorithm were also used in
haplotype analysis using WHAP [27], as implemented in PLINK
[22].
Validation Sample
We sought to validate any novel findings from the WGHS in an
independent replication sample comprised of 455 non-diabetic
Caucasian participants recruited from the Boston metropolitan
area [28]. A history of diabetes, or use of anti-diabetic
medications, and/or fasting glucose levels .125 mg/dL, or
abnormal oral glucose tolerance test results were used to exclude
persons with diabetes in this cohort. Glycated hemoglobin was
measured with an HPLC assay that serves as a primary reference
assay for the National Glycohemoglobin Standardization Pro-
gram, with coefficients of variation ,2.5% for low and high
standards. Genotype determination was performed with an ABI
fluorescence-based allelic discrimination method (rs7072268) [29]
or a single reaction kinetic thermal cycling method (rs2305198)
[30]. The study was approved by the Brigham and Women’s
Hospital and Massachusetts General Hospital Institutional Review
Boards for human subjects research.
Results
Clinical characteristics of the 14,618 non-diabetic women in the
primary WGHS analysis and of the 455 non-diabetic men and
women in the external validation cohort are provided in
Supplementary Table S1. Results of the genome-wide association
analysis of adjusted baseline glycated hemoglobin concentration
are presented in Table 1, which includes all SNPs with P-value
lower than 10
26. Six SNPs at three different loci – G6PC2, GCK
and HK1 - had an association P-value lower than our previously
defined genome-wide significance threshold of 5610
28:
rs1402837, rs560887 and rs6709087 at G6PC2; rs730497 and
rs4607517 at GCK; rs7072268 at HK1. In addition, two SNPs,
one at the HK1 locus and one at the SCL30A8 locus, had
association P-values just above this threshold level (5.5610
28 and
9.8610
28, respectively). Genetic context of all these loci is
presented in Figure 1 along with the 2log10 transformed P-values.
To define further the extent of genetic associations at these 4
loci, we applied a forward model selection algorithm to each of
them, identifying SNPs that were non-redundantly associated with
glycated hemoglobin. Briefly, 38 SNPs at GCK, 31 at SLC30A8,
41 at HK1 and 44 at G6PC2 were initially assessed for possible
inclusion in a multiple linear regression model. Using a P-value
cut-off of 3610
24 to account for the 154 SNPs considered, 5 SNPs
were selected, representing the lead SNP at each of the 4 loci
considered plus one SNP (rs2305198; located at 70799 Kb on
chromosome 10) at the HK1 locus (see Table 2). Interestingly, this
later SNP (rs2305198; HK1) was marginally significant in
univariable analysis (p=0.02), illustrating that its inclusion in the
model and significant association are conditional on the genotypes
at rs7072268 (HK1). Multiple regression beta coefficients and P-
values of the 5 SNPs selected are shown in Table 2 and range from
5.4610
28 to 1.8610
225. Shown in Figure 2 are the quantile-
quantile plots of association P-values before and after adjusting
glycated hemoglobin concentration for the combined effect of
these 5 SNPs. Among these SNPs, there was no strong evidence
for non-additive effects of the minor allele as judged by lack of
significance for a likelihood ratio test comparing the additive
regression model to an alternative genotype model with an
additional degree of freedom. No pairwise gene-gene interaction
was observed between any of the model selected SNPs. That is, we
tested every possible 2-SNPs combination among these 5 SNPs.
We sought to replicate the novel association between glycated
hemoglobin level and HK1 SNPs (rs2305198 and rs7072268) in
the external validation sample of 455 non-diabetic men and
women from the Boston metropolitan area. We included both
SNPs (assuming an additive genetic effect) in a multiple regression
model that also included age, sex, menopause and BMI as
covariates. Both SNPs were successfully replicated, with two-sided
P-values of 0.027 (rs2305198) and 0.050 (rs7072268), and both
with consistent direction of effect. Furthermore, the effect size (i.e.
beta coefficients) was larger than in the WGHS, with changes in
glycated hemoglobin of 0.101% (rs2305198) and 0.085%
(rs7072268) per allele in the replication sample, as opposed to
0.041% and 0.046% respectively in the WGHS. The association
was validated in both men (N=204) and women (N=251),
without any evidence of interaction with sex (data not shown).
Both SNPs were in Hardy-Weinberg equilibrium, had allelic
frequencies consistent with the ones observed in WGHS, and were
successfully genotyped in over 93% of individuals. Of note, the P-
values for rs2305198 and rs7072268 were non-significant (p.0.05)
when each SNP was analyzed separately in a linear model.
Overall, the P-values for rs2305198 and rs7072268 when both
SNPs were included in a multiple regression model that used the
combined WGHS and replication sample were 9.9610
220 and
1.7610
225, respectively.
The 2 SNPs at the HK1 locus selected by our algorithm were
also used in haplotype analysis in WGHS individuals (Table 3).
The estimate of the proportion of variance attributable to
haplotypes, as well as their regression coefficients, is consistent
with the linear model of these same SNPs, reinforcing the
adequacy of the multiple linear model to explain the association.
Linkage disequilibrium between these two HK1 SNPs was 0.49 for
r
2 and 0.90 for D’. The 2 SNPs at HK1 collectively explained
0.7% of the total variance in glycated hemoglobin concentration,
whereas the G6PC2 SNP (rs1402837) explained 0.2%, the GCK
SNP (rs730497) 0.3% and the SLC30A8 SNP (rs13266634) 0.2%.
In comparison, clinical covariates accounted for 9.5% of the
variance (Table 4), and together the candidate loci and the clinical
variables accounted for 10.9% of total variance. As was the case in
the WGHS, haplotype analysis of the replication sample yielded
similar results as the multivariable linear regression, albeit with
lesser statistical significance (data not shown).
Since several SNPs have been unequivocally associated with
type 2 diabetes, we tested whether these ‘‘candidate’’ SNPs
[1,4,31,32] were associated with glycated hemoglobin as well
(Table 5). When a SNP was not directly typed in WGHS, we used
HapMap CEU linkage disequilibrium data to find the WGHS
SNP with the highest r
2 with that SNP. While all SNPs tested had
a direction of association consistent with their effect on the risk of
diabetes, only 10 SNPs had a (one-sided) P-value lower than 0.05
(Table 5). Overall, the one-sided association P-value for the 19
SNPs taken together (i.e. the P-value obtained by combining all 19
one-sided P-values; this was done using Fisher’s method for
combining P-values from independent tests) was 3.0610
222. The
P-value was 8.5610
29 when the SLC30A8 SNP rs13266634 and
the GCK SNP rs730497 were removed. It has previously been
shown that the metabolic effects of rs8050136 (FTO locus) are
mediated mainly through increased body weight [33,34]. Adjust-
ment of glycated hemoglobin for BMI would therefore be expected
to dampen the association of rs8050136 (FTO locus) with glycated
hemoglobin level. Indeed, non-adjusted glycated hemoglobin
showed stronger association with rs8051136 (p=0.007).
Association of HK1 with Glycated Hemoglobin
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26 for Association with Adjusted Glycated Hemoglobin.
SNP Locus Position (kb) Nearest Gene Function MAF
a HW
b Beta (%HbA1c)
c P-Value
c FDR
e
rs1402837 2q24.3 169466 G6PC2 - 0.23 0.87 0.023 6.8E-10 7.8E-05
rs560887 2q24.3 169471 G6PC2 intron 0.29 0.88 20.020 1.2E-08 8.1E-04
rs563694 2q24.3 169482 G6PC2 - 0.34 0.76 20.017 2.5E-07 7.8E-03
rs552976 2q24.3 169500 G6PC2 intron 0.35 0.97 20.018 1.7E-07 5.8E-03
rs6709087 2q24.3 169507 G6PC2 intron 0.23 0.68 0.021 2.3E-08 1.3E-03
rs730497 7p13 44190 GCK intron 0.17 0.82 0.030 2.8E-12 9.6E-07
rs4607517 7p13 44202 GCK - 0.17 0.67 0.029 6.2E-12 1.1E-06
rs13266634 8q24.11 118254 SLC30A8 NSC
d 0.30 0.50 20.019 9.8E-08 3.8E-03
rs906216 10q21.3 70768 HK1 intron 0.44 0.15 20.017 5.5E-08 2.7E-03
rs7072268 10q21.3 70770 HK1 intron 0.50 0.10 0.018 6.4E-09 5.5E-04
aMAF: Minor Allele Frequency.
bHW: Deviation from Hardy-Weinberg equilibrium P-value.
cAll analyses were performed using adjusted glycated hemoglobin values (see text for details).
dNSC: Non-Synonymous Coding SNP.
eFDR: False Discovery Rate.
doi:10.1371/journal.pgen.1000312.t001
Figure 1. Genetic Context of Significant Associations. Genomic context for each of four loci with significant association with glycated
hemoglobin levels. (A) G6PC2 locus (2q24.3); (B) GCK locus (19p13.2); (C) SLC30A8 locus (8q24.11); (D) HK1 locus (10q21.3). Upper panel: Genes from
RefSeq release 25. Only one isoform is shown when multiple splicing variants are known. Lower Panel: SNPs are shown according to their physical
location and 2log10 P-values for association with glycated hemoglobin. At each locus, the SNP with the lowest P-value is represented by a black dot.
The color of each other SNP was determined according to its linkage disequilibrium (r
2) with the SNP with the lowest P-value, with colors varying
from blue (r
2=0) to red (r
2=1). In Figure 1-D, the chromosomal position of rs2305198 is shown as this SNP was selected by the model selection
algorithm in addition to the SNP with the lowest P-value (see text for details). The red line represents the genome-wide significance threshold of
5610
28. Also shown is the genetic distance in cM from the lowest P-value SNP (light grey line) along with the position of recombination hotspots
(light grey vertical bars). Recombination rates and hotspots are based on HapMap data, as described by McVean et al.[46] and Winckler et al.[47].
doi:10.1371/journal.pgen.1000312.g001
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Four loci – GCK, SLC30A8, HK1 and G6PC2 – have been
identified in this report as being significantly associated with
glycated hemoglobin levels in non-diabetic individuals. While
genetic variants of GCK [2–4] and G6PC2 [5,6] are known to
influence fasting glucose concentrations in non-diabetics, the
association with the diabetes gene SLC30A8 [7] has not been
previously identified. In contrast, genetic associations with glycated
hemoglobin have previously been described with the candidate
genes calpain-10 (CAPN10) [35], resistin (RETN) and adiponectin
(ADIPOQ) loci [36], although none of these associations were
replicated in our data.
The most striking association observed in the current report
involves HK1, which is a novel finding. Four different hexokinase
isozymes, named type I, II, III and glucokinase (GCK), are present
in mammalian tissues. Hexokinase type I (HK1) is the predom-
inant isoform found in erythrocytes, although it is also expressed in
other human tissues that depend strongly on glucose utilization for
their physiologic functioning, such as brain and muscle [37,38].
Despite this wide tissue distribution, the main clinical manifesta-
tion of rare HK1 mutations is severe nonspherocytic hemolytic
anemia [38]. To our knowledge, no common genetic variation has
previously been correlated with any phenotype. The reason why
erythrocytes are particularly susceptible to these rare mutations is
not clear, but the prevailing assumption is that tissues strongly
dependent on HK1, such as erythrocytes, might be preferably
affected. One hypothesis to explain the strong association of
rs7072268 and rs2305198 with glycated hemoglobin levels is that
these SNPs affect hexokinase concentration or activity in
Table 2. Multiple Linear Regression Statistics of SNPs Retained by the Forward Model Selection Algorithm.
Locus SNP Nearest Gene Function MAF
a HW
b Beta
c P-Value
c
2q24.3 rs1402837 G6PC2 - 0.23 0.87 0.0236 4.7E-10
7p13 rs730497 GCK intron 0.17 0.82 0.0291 5.7E-12
8q24.11 rs13266634 SLC30A8 NS
d 0.30 0.50 20.0189 5.4E-08
10q21.3 rs7072268 HK1 intron 0.50 0.10 0.0465 1.8E-25
10q21.3 rs2305198 HK1 intron 0.38 0.05 0.0409 4.3E-19
aMAF: Minor Allele Frequency.
bHW: Deviation from Hardy-Weinberg equilibrium P-value.
cAll analyses were performed using adjusted glycated hemoglobin values (see text for details). Beta coefficients and P-values were derived form a multiple linear model
that included all 5 SNPs.
dNS: Non-Synonymous Coding SNP.
doi:10.1371/journal.pgen.1000312.t002
Figure 2. Quantile-Quantile plot of Glycated Hemoglobin Association P-Values. The quantile-quantile plot of glycated hemoglobin
association P-values is shown on the left. On the right, the same quantile-quantile plot is shown, but after adjusting glycated hemoglobin values for
the additive genetic effect of the 5 SNPs retained by the model selection algorithm (rs1402837, rs730497, rs13266634, rs7072268 and rs2305198; see
text for details).
doi:10.1371/journal.pgen.1000312.g002
Table 3. Haplotype Analysis of rs7072268 and rs2305198
(HK1 locus) in Relation to Adjusted Glycated Hemoglobin.
Haplotype Frequency
Beta
(%HbA1c) P-Value
rs7072268 rs2305198
A G 0.02 0.033 0.012
G G 0.36 0.006 0.095
A A 0.48 0.017 2.2E-07
G A 0.14 20.049 1.5E-26
The omnibus (3 df) p-value from the joint haplotype analysis is 2.1E-25.
doi:10.1371/journal.pgen.1000312.t003
Association of HK1 with Glycated Hemoglobin
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Since intra-erythrocyte glucose concentration is thought to be the
main determinant of hemoglobin glycation rate [39] and
hexokinase is the initial and rate-limiting enzymatic step in
erythrocyte glucose metabolism, after glucose transporter mediat-
ed diffusion, it is likely that variations in HK1 activity would affect
glycation. Alternatively, genetic variations at HK1 might modulate
systemic glucose metabolism, raising the possibility that these
variations are associated with the risk of incident diabetes. Indeed,
HK1 is expressed in muscle, an insulin-sensitive tissue recognized
for its importance in glucose metabolism.
SLC30A8 functions as a zinc transporter in secretory vesicles of
pancreatic beta cells, providing zinc for insulin maturation and
storage [40,41]. A coding non-synonymous polymorphism of
SLC30A8 (R325W; rs13266634) has been demonstrated to be
protective for type 2 diabetes [32,42–45] and was shown to
influence insulin secretion following an intravenous glucose
challenge [7]. In accordance with these results, that same coding
SNP was associated with lower glycated hemoglobin in our study.
Because many genetic variants have been previously associated
with the risk of type 2 diabetes, we also tested these for association
with glycated hemoglobin. Although not genome-wide significant,
all of these associations had a consistent direction of effect (as
compared with their association with diabetes). The low combined
P-value shows that it is very unlikely that these glycated
hemoglobin associations had such a consistent direction of effect
by chance alone, suggesting that they likely reflect underlying
‘‘true’’ associations. Furthermore, it also suggests that if we had
analyzed a much bigger sample, some of these associations might
have become genome-wide significant. To address the possibility
that the very low P-value from the analysis of all 19 SNPs stems
solely from the inclusion of the very significant SLC30A8 and
GCK SNPs, we repeated the procedure using only the weakly
associated SNPs as a sensitivity analysis, with similar results. It
therefore appears that genetic variations affecting the risk of future
diabetes do not necessarily have a marked impact on glycated
hemoglobin in healthy women, pointing to different, yet partially
overlapping, genetic architectures for glycated hemoglobin and
diabetes.
The limitations of this study include less than certain
elimination of diabetic subjects in the WGHS cohort, since we
did not perform oral glucose tolerance testing. Therefore, some
Table 4. Partition of Glycated Hemoglobin Variance
According to Genetic and Clinical Variables.
Category Variable Variable R
2 Category R
2
Clinical Covariates Age 0.0354 0.0946
Body Mass Index 0.0585
Menopause Status 0.0006
2q24.3 (G6PC2) Locus rs1402837 0.0024 0.0024
7p13 (GCK) Locus rs730497 0.0029 0.0029
8q24 (SLC30A8) Locus rs13266634 0.0019 0.0019
10q21.3 (HK1) Locus rs7072268 0.0021 0.0070
rs2305198 0.0049
TOTAL 0.1088
doi:10.1371/journal.pgen.1000312.t004
Table 5. Association of Glycated Hemoglobin with Type II Diabetes Candidate SNPs.
Gene(s) Candidate SNP Best WGHS Proxy r
2 D’ Beta (%HbA1c)
P-Value
(one-sided)
Direction of Effect
in Agreement
ADAMTS9 rs4607103 rs4132228 0.78 1 20.004 0.11 YES
CDC123,CAMK1D rs12779790 rs11257622 0.79 0.95 0.006 0.07 YES
CDKAL1 rs10946398 rs4712523 1 1 0.004 0.11 YES
CDKN2A-2B rs10811661 rs2383208 1 1 20.008 0.02 YES
FTO rs8050136 rs8050136 1 1 0.003 0.18 YES
GCK rs1799884 rs730497 1 1 0.030 1.4E-12 YES
GCKR rs780094 rs780094 1 1 20.007 0.01 YES
HHEX-IDE rs1111875 rs1111875 1 1 20.008 4.8E-03 YES
IGF2BP2 rs4402960 rs1470579 1 1 0.008 0.01 YES
JAZF1 rs864745 rs1635852 0.97 1 20.001 0.34 YES
KCNJ11 rs5215 rs5215 1 1 0.002 0.28 YES
NOTCH2 rs10923931 rs2793831 1 1 0.001 0.44 YES
PPARG rs1801282 rs1899951 1 1 20.008 0.05 YES
SLC30A8 rs13266634 rs13266634 1 1 20.019 4.9E-08 YES
TCF2 rs4430796 rs7501939 0.76 1 0.007 0.02 YES
TCF7L2 rs7901695 rs7903146 0.80 0.95 0.009 3.5E-03 YES
THADA rs7578597 rs6708660 0.16 1 20.007 0.01 YES
TSPAN8,LGR5 rs7961581 rs1353362 0.96 1 0.005 0.10 YES
WFS1 rs10010131 rs10012946 1 1 20.004 0.12 YES
All analyses were performed using adjusted glycated hemoglobin values (see text for details).
Linkage disequilibrium between candidate SNPs and their best WGHS proxies (r
2 and D’) were derived from HapMap data build 35 (CEU individuals).
One-sided P-values equal or lower than 0.05 are shown in bold.
doi:10.1371/journal.pgen.1000312.t005
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that population. However, we believe it is unlikely this would have
affected the results for two reasons. First, when we reproduced our
analysis using only women with glycated hemoglobin lower than
6.0%, we obtained similar results. Second, we were able to
replicate our novel HK1 findings in the validation cohort in which
OGTT was used to eliminate diabetic participants. Although HK1
polymorphisms are associated with glycated hemoglobin levels, the
functional consequences of these polymorphisms needs to be
established.
In this report, we demonstrate that glycated hemoglobin levels
in non-diabetic women are affected by genetic variation at the
GCK, SLC30A8, G6PC2 and HK1 loci. While associations at the
GCK, SLC30A8 and G6PC2 loci confirm or extend previous
work done on the genetic basis of diabetes or fasting glucose, our
replicated findings at HK1 are novel. It will be of considerable
interest to study HK1 in non-Caucasian populations, as well as in
pre-diabetic and diabetic populations, although the confounding
effects of treatment might obscure any role of these polymorphisms
in the diabetic population. This hypothesis generating genetic
observation paves the way for further studies of the role of HK1 in
hemoglobin glycation, glucose metabolism and diabetes. Whether
the differences in hemoglobin glycation associated with genetic
polymorphisms demonstrated herein are paralleled by differences
in glycation in other tissues that are thought to underlie long-term
complications of diabetes remains an open question.
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